While Vivus Inc.’s recently approved obesity drug Qnexa inspired talk that it would be a blockbuster like weight-loss drug Lipitor, Menlo Park-based Corcept’s Korlym won approval Feb. 17 for a drug aimed at roughly 5,000 to 10,000 patients with Cushing’s syndrome. That's a mere fraction of Qnexa's potential market.
Belanoff spoke with me recently about Corcept, its strategy for Korlym and how he celebrated Korlym’s approval, which earned him a $481,097 bonus.
No comments:
Post a Comment